Key Drivers
- Very high gross
- Large operating losses
- Extreme R&D intensity
AIAI Summary
Ionis's shift from R&D to multi‑product commercialization means the investment hinges less on pipeline optionality and more on near‑term commercial execution and cash‑management (Can Tryngolza scale quickly enough to avoid dilutive refinancing?). Key actionable watchpoints: sustained quarterly revenue beats, clear payer agreements/pricing for core launches, and avoiding an external financing event in 2025.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high gross
- •Large operating losses
- •Extreme R&D intensity
IONS has strong liquidity and exceptionally high gross margin but is loss-making with extreme R&D spend, high leverage, negative cash flow, and rich valuation that prices in future R&D success.
Price Behavior
Key Price Behavior Insights:
- •Below last-month SMA
- •Low-$70s support
- •Tiered resistance
IONS is in a short-term downtrend—down ~14–15% over the last month, trading below the last-month SMA (~$76.8) with local support at $70–72 and resistance near $76.8 and $83–85; a sustained move above the SMA would be constructive, while a break below the low-$70s would extend the bearish case.
~14–15% decline from $83.15 to $70.99 over the last month
Sentiment & News
Key News Insights:
- •Tryngolza upside
- •Mixed guidance
- •Insider selling
Ionis flagged stronger clinical and peak-revenue prospects (Tryngolza >$2B) and disciplined balance-sheet moves amid mixed near-term guidance and notable insider selling.
Positive long-term revenue and cash-flow guidance support valuation upside, but near-term sentiment may remain pressured by conservative guidance and insider exits
Similar Companies in Healthcare
Other companies in the same sector with AI ratings